In recent years, Longxi County has seized the opportunity of cooperation between the east and the west, actively built nests to attract phoenixes, and a large number of well-known domestic pharmaceutical companies have come to Longxi and settled in Longxi. Gansu Chenlan Biotechnology Co., Ltd. is a key landing project of Qingdao Dingxi East-West Cooperation. The implementation of the project has opened up new development space and brought new development opportunities for the high-value development of Longyao.
Walking into the R&D and testing center of Gansu Chenlan Biotechnology Co., Ltd., technicians are in full swing to carry out product R&D, testing and testing.
Chen Li, head of the testing center of Gansu Chenlan Biotechnology Co., Ltd.: This is the two new products we are currently developing, Codonopsis oligosaccharides and Astragalus oligosaccharides, which are the solubility experiments of our Party Ginseng oligosaccharides, and this is the determination of our content.
Gansu Chenlan Biotechnology Co., Ltd. is located at No. 1, Yaodu Avenue, Wenfeng Town, Longxi County, and is a wholly-owned subsidiary of Qingdao Chenlan Health Industry Group Co., Ltd., which is committed to the production of traditional Chinese medicine extracts, pharmaceutical production, food production, health food production, marine bioactive substance extraction, purification, synthesis technology research and development, etc. The enterprise covers an area of 102.43 acres, with a total investment of 243 million yuan, which is implemented in the first and second phases, of which the first phase of the project has completed an investment of 130 million yuan, and the construction task has been completed in April 2022 and officially put into operation in July 2022. After it is put into production, it will process 6,000 tons of raw medicinal materials such as Codonopsis, Astragalus membranaceus, and Angelica sinensis, and produce 500 tons of Chinese herbal medicine extracts annually. Since it was put into production, it has successively developed 6 traditional Chinese medicine compound extracts, 1 marine extract, and 1 medicinal and edible homologous solid beverage.
Mo Shaoliang, deputy general manager of Gansu Chenlan Biotechnology Co., Ltd.: In 2022, we will jointly develop this product (Radix Radix Radix Yam Compound Powder Solid Hard Material) jointly developed by Shenzhen Beijing University of Traditional Chinese Medicine, which is a food with the same origin as medicine and food made of Codonopsis and Astragalus membranaceus, and the main health care effect of this product is to strengthen the spleen and kidney and improve immunity. Since this product was put on the market, the response of customers has been particularly good, and the sales volume has been 70 million yuan.
Gansu Chenlan Biotechnology Co., Ltd. takes the deep processing of Longyao as the entry point, and builds a complete industrial chain from standardized harvesting, refined extraction to the R&D and production of new traditional Chinese medicine preparations and innovative drugs through the high-value development and industrialization demonstration of Longyao. With the project to lead the technology and promote the development with technology, effectively promote the cultivation and development of the traditional Chinese medicine health industry, and drive the development of upstream and downstream industries such as the standardized planting of Chinese herbal medicines, the research and development and production of traditional Chinese medicine formula granules, and the development of traditional Chinese medicine health products.
Mo Shaoliang, deputy general manager of Gansu Chenlan Biotechnology Co., Ltd.: Now the small test of Codonopsis and Astragalus oligosaccharide products we are developing has been successful. Next, we will move to mass production. In the next step, we will develop more big health products around Longxi Astragalus and Codonopsis ginseng.
In recent years, Gansu Chenlan Biotechnology Co., Ltd. has selected authentic Chinese herbal medicine varieties in Longxi in accordance with the development model of "large traditional Chinese medicine and whole industry chain", and carried out research on key technologies of the whole industry chain and key common technologies of traditional Chinese medicine manufacturing, especially the quality control technology of the manufacturing process and the research of high-end preparations of traditional Chinese medicine, so as to promote the modernization, large-scale and intensive development of the Longxi pharmaceutical industry. In 2023, Gansu Chenlan Biotechnology Co., Ltd. was rated as a pilot enterprise for the digital transformation of the traditional Chinese medicine decoction piece industry of the Ministry of Industry and Information Technology and an excellent innovation platform in the county in 2023.
Mo Shaoliang, deputy general manager of Gansu Chenlan Biotechnology Co., Ltd.: In the next step, our company will take the opportunity of east-west cooperation and pairing, rely on the advantages of authentic medicinal resources, continue to increase the scientific research of big health products, and strive to build a well-known Chinese medicine big health brand at home and abroad, so as to make positive contributions to the expansion and strengthening of the Chinese medicine industry and the health cause of Chinese medicine.
Longxi financial media all-media reporter Mo Hongxia